Market Overview
Market
Research Future (MRFR) has published a report about the global influenza
diagnostics market size expects 5.3% CAGR during the forecast period
between 2023-2032. In terms of cash, this market is expected to grow with USD
1.81 billion by 2032.
The
Influenza Diagnostics Market is witnessing steady growth driven by the
increasing prevalence of influenza worldwide. This market encompasses a wide
range of diagnostic tests including rapid influenza diagnostic tests (RIDTs),
molecular tests, and serological assays. Key factors influencing market growth
include the development of advanced diagnostic technologies, rising awareness
about early diagnosis, and government initiatives promoting influenza control.
Additionally, the COVID-19 pandemic has highlighted the importance of efficient
diagnostic tools, further propelling market expansion. However, challenges such
as the emergence of new influenza strains and stringent regulatory requirements
may hinder market growth. Overall, the market shows promising prospects with
continuous advancements in diagnostic techniques.
The
Influenza Diagnostics Market is experiencing a significant surge, driven by the
growing demand for rapid and accurate diagnostic solutions. Among the forefront
technologies shaping this market are Rapid
Influenza Diagnostic Tests (RIDTs) and Influenza Rapid Antigen Tests
(IRATs). These LSI keywords, rapid influenza diagnostic test, and influenza
rapid antigen test, highlight the pivotal role of these advanced diagnostic
tools in combating influenza outbreaks swiftly and effectively. RIDTs and IRATs
offer unparalleled speed and reliability, enabling healthcare professionals to
promptly identify and manage influenza cases, particularly during peak flu
seasons or outbreaks. The market for these tests is witnessing a notable expansion
owing to their user-friendly nature, which allows for quick and convenient
on-site testing, thereby streamlining the diagnostic process and facilitating
timely patient care.
Key Players
Global
influenza diagnostics market players include Alere (USA), BD (USA), Becton
Dickinson (USA), BioMérieux SA (France), Cepheid (USA), Hardy Diagnostics(USA),
LifeSign LLC.(USA), Meridian Bioscience, Inc.(USA), Quidel Corporation (USA),
Roche Molecular Systems Inc.(Switzerland), and Sekisui Diagnostics (USA).
Market Segmentation
The
global influenza diagnostics market is segmented on the basis of types, tests,
and region. The segmentation of types comprises of type A flu, type B flu, type
C flu. The three forms of type A are bird flu, seasonal flu, and Swine flu.
Bird Flu is known as Avian Influenza which is caused by viruses adapted to
birds. It can be caused by eating infected birds. Seasonal flu is common cold
whose viruses become active only during the change of seasons as human body
becomes adapt to the new season slowly. Similar to bird flu, swine flu is an
infection caused by any one of several types of swine influenza viruses. Swine
influenza virus (SIV) or swine-origin influenza virus (S-OIV) are the viruses
causing this infection. These viruses are found in pigs. Type B flu is found
only in humans. Influenza type B viruses are not classified by subtype and do
not cause pandemics. It is caused by a genus called Influenzavirus B which is
from the virus family Orthomyxoviridae. Type C Influenza viruses are from
Orthomyxoviridae family. They are not as severe as Type A or B but can cause
local epidemics.
On
the basis of tests, the market has been segmented into direct fluorescent
antibody (DFA) tests, molecular tests, nucleic acid sequence-based
amplification (NASBA) tests, rapid influenza detection tests (RIDT),
serological assays, simple amplification-based assays (SAMBA) and loop-mediated
isothermal amplification-based assays (LAMP). RITD is the most common test for
influenza, as it can confirm influenza in just 30 minutes.
Serological
assays are segmented into primary serological tests, secondary serological
tests, and tertiary serological tests. Primary serological tests cover
enzyme-linked immunosorbent assay (ELISA), immunofluorescent antibody technique
(IFAT) and radioimmunoassay (RIA). Secondary Serological tests include
agglutination tests, complement fixation tests (CFT), precipitation tests,
serum neutralization tests (SNT) and toxin-antitoxin test.
Regional Analysis
The
regional segmentation of the global influenza diagnostics market is into the
Americas (North America & South America), Europe, Asia Pacific, and Middle
East & Africa (MEA). North America is believed to be the largest market for
global influenza diagnostics due to advanced healthcare facilities and the
increasing presence of major market players in this region. Compared to North
America, South America is a moderately smaller market, but that is not due to
lack of demand but due to the lack of awareness, lack of advanced technology
and lesser budgets for healthcare. In North America, the largest markets are
Canada and the United States of America (USA).
After
North America, Europe is the largest market for influenza diagnostics. Here due
to reasons same as North America, Western Europe stands with the lion's share
in Europe market, compared to Eastern Europe. In Western Europe, the biggest
markets are France, Germany, Italy, Spain and the United Kingdom (UK), followed
by the rest of Europe.
During
the forecast period, Asia Pacific region is expected to experience large-scale
growth of influenza diagnostics market with China, India, Japan and South Korea
emerging as major markets. Remarkable growth is also expected in remaining
countries of Asia Pacific region.
However,
compared to the Asia Pacific, MEA is expected to have limited growth, with
Egypt, Saudi Arabia and the United Arab Emirates (UAE) emerging as the best
bets for influenza diagnostics market investors. The low market in the MEA
region is primarily due to the lack of technology and education.
For more information, Please Visit us @ Market
Research Future
